3 Biotechs With Potential Blockbusters Near the Finish Line

The past year has been one to remember for biotech investors. The FDA smashed through its previous record for new drug approvals in a single season, and a long list of experimental drugs getting close to the finish line promise to make 2019 just as interesting.

These experimental treatments aren't approved to treat anything yet, but their continued success could send shares of the drugmakers developing them soaring in the new year.